MAR 11, 2019 02:54 PM PDT

Fast-Acting Drug For Depression

WRITTEN BY: Nouran Amin

Many individuals going through depression gain little benefit from treatments whether drugs or talk therapy. Depression represents one of the greatest unmet needs in psychiatry. Now, the Food and Drug Administration (FDA) approved a fast-acting prescription antidepressant: a nasal spray version of the widely used anesthetic drug ketamine.

A colored positron emission tomography scan of the brain of a depressed person, highlighting regions (in red) where blood flow and metabolic activity are unusually low. CreditWDCN/Univ. College London, via Science Source.

“Thank goodness we now have something with a different mechanism of action than previous antidepressants,” said Dr. Erick Turner, a former F.D.A. reviewer and an associate professor of psychiatry at Oregon Health & Science University. “But I’m skeptical of the hype, because in this world it’s like Lucy holding the football for Charlie Brown: Each time we get our hopes up, the football gets pulled away.”

The newly approved fast-acting drug, now called esketamine, will bring on a shift from the Prozac era of antidepressant drugs. The spray was developed by Janssen Pharmaceuticals Inc., a branch of Johnson & Johnson, and will be marketed under the name Spravato.

“These are exciting times, for sure,” said Dr. Todd Gould, an associate professor of psychiatry in the University of Maryland School of Medicine. “We have drugs that work rapidly to treat a very severe illness.”

Spravato (esketamine) “works in a different way than traditional antidepressants,” with results in a matter of hours.

Credit: Janssen Pharmaceuticals, Inc.

Esketamine provides renewed hope in treating serious mood problems. Current drug treatments, like Prozac and similar drugs, work to enhance the activity of brain chemical like messengers like serotonin—however, these drugs take weeks or even months for their effects to be felt.

“We’ve had nothing new in 30 years,” said Steven Hollon, a professor of psychiatry and behavior sciences at Vanderbilt University. “So if this drug is an effective way to get a more rapid response in people who are treatment resistant, and we can use it safely, then it could be a godsend.”

Learn more:

Source: NY Times

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Making Cancer Disappear?
Neuroblastoma is one of the most common childhood cancers and the leading cause of cancer deaths among pediatric patients younger than 5. The cancer is fre...
NOV 25, 2018
Microbiology
NOV 25, 2018
Researchers Learn How Hantavirus Infects Cells
First identified in 1993, hantavirus infections can cause dangerous and potentially deadly respiratory infections....
DEC 13, 2018
Drug Discovery
DEC 13, 2018
First Non-Opioid Drug?
In a study published in the medical journal—PAIN, a non-opioid drug compound discovered by researchers from the National Institute of Health (NIH)&md...
DEC 15, 2018
Drug Discovery
DEC 15, 2018
Ebola-Fighting Protein Paves The Way For New Drugs
In a study published in Cell, research at Northwestern University School of Medicine has involved scientists discovering a human protein that could be...
MAR 13, 2019
Drug Discovery
MAR 13, 2019
Combination Immunotherapy Stops Liver Cancer Growth
The number of individuals diagnosed with liver cancer is on the rise and current therapies are largely ineffective. However, new preclinical data from the ...
MAR 15, 2019
Drug Discovery
MAR 15, 2019
Vaccine Blocks Osteoarthritis Pain in Mice
A virus-like particle vaccine was developed to stop chronic pain caused by osteoarthritis inhibiting a nerve growth factor (NGF). The vaccine was administe...
Loading Comments...